- Home
- INO vs ARMP Comparison
INO vs ARMP Comparison
Compare INO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- ARMP
- Stock Information
- Founded
- INO 1979
- ARMP N/A
- Country
- INO United States
- ARMP United States
- Employees
- INO N/A
- ARMP N/A
- Industry
- INO Medical/Dental Instruments
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INO Health Care
- ARMP Health Care
- Exchange
- INO Nasdaq
- ARMP Nasdaq
- Market Cap
- INO 136.6M
- ARMP 125.7M
- IPO Year
- INO 1998
- ARMP N/A
- Fundamental
- Price
- INO $1.77
- ARMP $6.68
- Analyst Decision
- INO Buy
- ARMP Strong Buy
- Analyst Count
- INO 5
- ARMP 1
- Target Price
- INO $9.00
- ARMP $9.00
- AVG Volume (30 Days)
- INO 1.4M
- ARMP 174.8K
- Earning Date
- INO 11-10-2025
- ARMP 11-12-2025
- Dividend Yield
- INO N/A
- ARMP N/A
- EPS Growth
- INO N/A
- ARMP N/A
- EPS
- INO N/A
- ARMP N/A
- Revenue
- INO $182,337.00
- ARMP $5,054,000.00
- Revenue This Year
- INO N/A
- ARMP $8.43
- Revenue Next Year
- INO $14,751.49
- ARMP N/A
- P/E Ratio
- INO N/A
- ARMP N/A
- Revenue Growth
- INO N/A
- ARMP N/A
- 52 Week Low
- INO $1.30
- ARMP $0.90
- 52 Week High
- INO $4.61
- ARMP $16.34
- Technical
- Relative Strength Index (RSI)
- INO 31.56
- ARMP 62.66
- Support Level
- INO $1.93
- ARMP $5.83
- Resistance Level
- INO $2.11
- ARMP $7.30
- Average True Range (ATR)
- INO 0.14
- ARMP 0.75
- MACD
- INO -0.05
- ARMP 0.04
- Stochastic Oscillator
- INO 0.43
- ARMP 80.54
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.